Yahoo Finance

Analyst Bullish on Beam Therapeutics (BEAM) Over Drug Program Trajectory

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug

An independent arbitration panel ruled that developing Prime Medicine’s experimental drug for Alpha-1 Antitrypsin Deficiency ...
Nasdaq

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the ...
manilatimes

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported financial ...
Post-Bulletin

'Mayo brand name' gives proton beam program the edge

Mayo Clinic's $188 million Proton Beam Therapy Program is still in the process of ramping up, but it's already turning heads within a struggling niche in the medical industry. Since opening June 23, ...
Finanznachrichten

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM-304 Anticipated in 2026 Updated Phase 1/2 Data and Next ...